Good Health Medicine

Main Menu

  • Home
  • Health medicine
  • Dietary supplements
  • Dietary nutrition
  • Alternative medication
  • Medicine price

Good Health Medicine

Header Banner

Good Health Medicine

  • Home
  • Health medicine
  • Dietary supplements
  • Dietary nutrition
  • Alternative medication
  • Medicine price
Dietary nutrition
Home›Dietary nutrition›NNB Nutrition Files New Use Patent for L-Ergothioneine to Reduce and Prevent Eye Aging

NNB Nutrition Files New Use Patent for L-Ergothioneine to Reduce and Prevent Eye Aging

By Rebecca C. Myers
May 30, 2022
0
0

MitoPrime®(L-Ergothioneine), known as the new “longevity vitamin”, is often considered the most complete oral antioxidant known, which exhibits profound anti-inflammatory actions and protects DNA and mtDNA.

NNB Nutrition (https://nnbnutrition.com/), a leading branded ingredient supplier and creator, delivers new and innovative ingredients with an elite global team of scientists, recently announced that it has filed a PCT patent ( PCT/CN2021/ 101541) on the use of MitoPrime® (L-Ergothioneine) to relieve and prevent age-related macular degeneration (AMD). In pursuing this patent, NNB discovered that MitoPrime can actively prevent age-associated visual degeneration in mammals.

Age-related macular degeneration consists of a phenomenon including eyestrain, blurred vision, dry eyes, eyestrain and eventually even blindness, etc. more than 25% of people over 75. In the United States alone, 2 million people have advanced AMD and more than 8 million people have an intermediate form of this age-related degeneration. These figures are expected to increase by 50% in 2022. In Saudi Arabia, AMD accounts for 3.3% of the leading causes of blindness in people over 50. As human society ages globally, especially beyond the age of 40, senescence and degeneration of ocular organ function become more common, which could lead to inconveniences for individuals and increase the social burden. Elderly people with senescence and degeneration of eye organ function can be called age-related visual degeneration. Age-related visual degeneration can damage the outer retina, such as the retinal pigment epithelium (RPE, an important role in light absorption), Bruch’s membrane (BM), and the underlying choroid (choriocapillaris ) and photoreceptors.[1]. Therefore, focusing on the eye health of the elderly is becoming a new trend in today’s healthcare product market.

For this reason, NNB found that MitoPrime surely added more market value. Not only that, but NNB’s patent experiment was also carefully designed: NNB used zebrafish as an experimental object in the patent experiment, and the main reason is that the fundus model of zebrafish is recognized in academic circles as the most similar model to the human eye. . Meanwhile, zebrafish visual fatigue is also very similar to that of humans[2]. Therefore, as long as the efficacy of the substance in the eyes of zebrafish is proven, it can be concluded that it will have the same efficacy in the human body. NNB is also the first company to use zebrafish to study the effect of EGT on eye health, which is also an innovative experiment of great importance in the dietary supplement industry.

In the nnb experimental report, researchers used inducing factors to cause zebrafish to first show symptoms of age-related macular degeneration, then these zebrafish were pooled and placed in water containing different substances. Researchers found that zebrafish placed in water containing MitoPrime had a significant reduction in the degree of macular degeneration, as well as improved eye health; the effect was even comparable to that of zebrafish placed in a liquid medicine specially designed to relieve macular degeneration.

This research published by NNB perfectly confirmed the role of MitoPrime (Ergothioneine) in the relief of age-related macular degeneration. Therefore, this patent filed by NNB claimed that L-ergothioneine can be used as an active ingredient to alleviate and prevent age-related visual degeneration in aged mammals. It can be said that this patented experiment has greatly expanded the use of MitoPrime. For brand owners who plan to develop eye health product lines, MitoPrime fits their needs perfectly.

Afight MitoPrime®

MitoPrime®, NNB’s pure ergothioneine, is NNB Biotech’s bio-perfected form of the histone derivative L-ergothioneine which is now supported by over 15 studies including clinical trials, human cells and pharmaceutical model C Elegans. MitoPrime® L-ergothioneine is a naturally water-soluble amino acid with a powerful energizing antioxidant property, which benefits longevity, antioxidant, DNA and genome stability, boosting immunity , anti-inflammatory, and cellular and organ health, and can be formulated or function as the sole active ingredient. It is 100% natural, non-GMO and contains no additives of any kind.

NNB believes that regulatory certification such as GRAS and FSSAI, as well as clinical trials and patents can add more value to the product itself, and also allow MitoPrime to be used more widely, such as in daily supplements, skin care, cosmetics, food, beverages, etc. NNB also looks forward to discussing broader application scenarios of MitoPrime with you.

Claims of MitoPrime®

Can be used as an active ingredient to alleviate and prevent age-related visual degeneration in old mammals (mammals include humans)

MitoPrime® can be prepared as a nutritional or drinkable or pabular or pharmaceutical composition as such and used in the food, beverage, nutritional or pharmaceutical field –

– Attenuation of skin aging, improvement of radiance and luminosity

– The antioxidant capacity is 10 times greater than that of polyphenols in fruits and vegetables

– Shown 34 times more effective than glutathione

– Long half-life of antioxidant compounds, 32 days (glutathione half-life is 8 minutes)

– Removes DNA damaging acids

About NNB

NNB is the leading ingredient-focused biotechnology company employing over 100 research scientists from over 10 countries who research, design and supply unique ingredients to this industry to maximize health, increase performance, increase longevity and improve health. ‘appearance. NNB promotes partnerships with companies in the fields of nutraceuticals, pharmaceuticals and medical research.

References:

1. Zhao, Z., et al., Age-related retinopathy in NRF2-deficient mice. PLoS ONE, 2011. 6(4): p. e19456-e19456.

2. Kajimura, Shingo, Aida et al. Understanding Hypoxia-induced Gene Expression in Early Development: In Vitro and In Vivo Analysis of Hypoxia-Inducible Factor 1-regulated Insulin-regulated Zebrafish Growth Factor 1 Gene Expression.[J]. Molecular and Cellular Biology, 2006.

Media Contact
Company Name: Nanjing Nutrabuilding Biotech Co., LTD. (NNB Nutrition)
Contact person: Amanda
E-mail: Send an email
Call: +86-25 5881 2792
Address:No. 270 Jiqingmen Street, Suning Huigu, Building E6, Room 2105
Town: Nankeen
Country: China
Website: https://www.nnbnutrition.com/

Related posts:

  1. USDA to reshape our view of dietary nutrition
  2. Study, Health News, ET HealthWorld
  3. QUINN ON NUTRITION: The Importance of Dietary Fiber | Regain health
  4. Makers Nutrition wins 10 Globees® at the 2021 CEO World Awards | New
  • Alternative medication
  • Dietary nutrition
  • Dietary supplements
  • Health medicine
  • Medicine price
  • Survey compares how consumers and nutrition experts rate healthy foods – AgriNews
  • Bone & Joint Health Supplements Market to Witness a CAGR of 8% (2022-2028) Driven by Growing Prevalence of Orthopedic Disorders and Micronutrient Deficiencies | UnivDatos Market Overview
  • Police arrest scammer entangling hundreds of IPB students in online loans
  • Know which one is better for nutrition, skin and health
  • Your answers on cancer: What to know about stomach cancer? | Health, Medicine and Fitness
  • November 2022
  • October 2022
  • September 2022
  • August 2022
  • July 2022
  • June 2022
  • May 2022
  • April 2022
  • March 2022
  • February 2022
  • January 2022
  • December 2021
  • November 2021
  • October 2021
  • September 2021
  • August 2021
  • July 2021
  • June 2021
  • May 2021
  • April 2021
  • March 2021
  • February 2021
  • January 2021
  • December 2020
  • November 2020
  • October 2020
  • August 2020
  • May 2020
  • March 2020
  • December 2019
  • November 2019
  • October 2019
  • September 2019
  • August 2019
  • June 2019
  • May 2019
  • April 2019
  • March 2019
  • February 2019
  • January 2019
  • December 2018
  • November 2018
  • October 2018
  • September 2018
  • August 2018
  • July 2018
  • June 2018
  • March 2018
  • February 2018
  • January 2018
  • November 2017
  • October 2017
  • September 2017
  • August 2017
  • August 2016
  • June 2016
  • May 2016
  • February 2016
  • October 2015
  • August 2015
  • April 2015
  • March 2014
  • December 2013
  • September 2012
  • October 2011
  • September 2011
  • July 2011
  • June 2011
  • April 2011
  • March 2011
  • March 2010
  • September 2007
  • Privacy Policy
  • Terms and Conditions